AA
EW icon

AlphaCentric Advisors’s Edwards Lifesciences EW Stock Holding History

AlphaCentric Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$691K Buy
+9,333
New +$653K 0.69% 41

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

AlphaCentric Advisors's EW Position: Q4 2024 in Review

AlphaCentric Advisors opened a new position in Edwards Lifesciences (EW) in Q4 2024: 9,333 shares worth $691K. The stake represents 0.69% of the portfolio and ranks #41 among its holdings.

1,228 funds tracked by Wall St. Rank hold EW as of Q4 2024.

  • AlphaCentric Advisors held 9,333 shares of Edwards Lifesciences worth $691K as of Q4 2024.
  • Edwards Lifesciences was a new AlphaCentric Advisors position in Q4 2024.
  • Edwards Lifesciences made up 0.69% of AlphaCentric Advisors's portfolio in Q4 2024, its #41 holding.
  • 1,228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.